Hematological Alterations Related to Treatment with Teriflunomide and Dimethyl Fumarate in Multiple Sclerosis

IF 1.6 Q3 CLINICAL NEUROLOGY

NeuroSci Pub Date : 2020-09-21 DOI:10.3390/NEUROSCI1010003

D. García-Estévez

{"title":"Hematological Alterations Related to Treatment with Teriflunomide and Dimethyl Fumarate in Multiple Sclerosis","authors":"D. García-Estévez","doi":"10.3390/NEUROSCI1010003","DOIUrl":null,"url":null,"abstract":"The exact mechanism of action of different modifying treatments in the evolutionary course of multiple sclerosis (MS) remains unknown, but it is assumed that they act upon the cells involved in acquired immunity. One effect of these treatments is the development of lymphopenia, which carries inherent safety risks. This study was conducted to understand the alterations that teriflunomide (TERI) and dimethyl fumarate (DMF) exert upon white blood cells in a series of patients with MS. This study included a total of 99 patients; 44 treated with DMF and 55 patients treated with TERI. Blood counts were evaluated at baseline and every 6 months in order to track the absolute leukocyte, lymphocyte, and neutrophil counts. Twelve months after starting treatment, we observed a significant decrease in leukocytes (21.1%), lymphocytes (39.1%), and neutrophils (10%) in the DMF group. In the TERI group, leukocytes decreased by 11.1%, lymphocytes by 8.1%, and neutrophils by 15.7%. Both TERI and DMF produced a significant decrease in leukocytes during the first year of treatment and this was mainly related with a decrease in neutrophils in the TERI group and a decrease in lymphocytes in the DMF group.","PeriodicalId":74294,"journal":{"name":"NeuroSci","volume":"7 1","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2020-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroSci","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/NEUROSCI1010003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

The exact mechanism of action of different modifying treatments in the evolutionary course of multiple sclerosis (MS) remains unknown, but it is assumed that they act upon the cells involved in acquired immunity. One effect of these treatments is the development of lymphopenia, which carries inherent safety risks. This study was conducted to understand the alterations that teriflunomide (TERI) and dimethyl fumarate (DMF) exert upon white blood cells in a series of patients with MS. This study included a total of 99 patients; 44 treated with DMF and 55 patients treated with TERI. Blood counts were evaluated at baseline and every 6 months in order to track the absolute leukocyte, lymphocyte, and neutrophil counts. Twelve months after starting treatment, we observed a significant decrease in leukocytes (21.1%), lymphocytes (39.1%), and neutrophils (10%) in the DMF group. In the TERI group, leukocytes decreased by 11.1%, lymphocytes by 8.1%, and neutrophils by 15.7%. Both TERI and DMF produced a significant decrease in leukocytes during the first year of treatment and this was mainly related with a decrease in neutrophils in the TERI group and a decrease in lymphocytes in the DMF group.

查看原文本刊更多论文

特立氟米特和富马酸二甲酯治疗多发性硬化症的血液学改变

不同修饰治疗在多发性硬化(MS)进化过程中的确切作用机制尚不清楚，但假设它们作用于参与获得性免疫的细胞。这些治疗的一个影响是淋巴细胞减少症的发展，这带有固有的安全风险。本研究旨在了解特立氟米特(teri氟米特，TERI)和富马酸二甲酯(DMF)对一系列多发性硬化症患者白细胞的影响。44例采用DMF治疗，55例采用TERI治疗。在基线和每6个月评估一次血细胞计数，以跟踪绝对白细胞、淋巴细胞和中性粒细胞计数。开始治疗12个月后，我们观察到DMF组白细胞(21.1%)、淋巴细胞(39.1%)和中性粒细胞(10%)显著下降。在TERI组，白细胞减少11.1%，淋巴细胞减少8.1%，中性粒细胞减少15.7%。在治疗的第一年，TERI和DMF都产生了白细胞的显著减少，这主要与TERI组中性粒细胞的减少和DMF组淋巴细胞的减少有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NeuroSci

自引率

0.00%

发文量

审稿时长

11 weeks